Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apitope Upbeat After Merck Returns Multiple Sclerosis Candidate

Executive Summary

With cladribine battling it out again with regulatory authorities for approval in multiple sclerosis, Merck decides to hand back rights to Apitope's Phase II MS drug candidate.

You may also be interested in...



ECTRIMS 2016: What Future For Merck KGaA’s Cladribine?

With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA is using ECTRIMS 2016 as the stage for numerous new presentations on the drug’s efficacy and safety. Data on this additional induction therapy are positive but regulators and the market could prove difficult to persuade.

Hemophilia A And Graves' Focus For Freshly Financed Apitope

Few will remember Apitope. Those that do will remember it had a good run in 2008, with a series A financing and a licensing deal with Merck Serono for its lead program in multiple sclerosis (MS), and then…near radio silence. Until now. Suddenly that distant MS candidate ATX MS 1467 is Merck Serono's second-to-last remaining hope as a successor to Rebif. And Apitope has two more interesting compounds ready for clinical testing – for hemophilia A and Graves' disease – and the money to fund them with a €12m series B financing announced this week. Scrip's Sukaina Virji caught up with CEO Dr Keith Martin.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel